Moderate
Probable
Description
Co-administration of escitalopram and sumatriptan may lead to serotonin syndrome, though clinical cases are less frequent than with tramadol combinations.
Mechanism
Escitalopram increases synaptic serotonin by inhibiting SERT; sumatriptan is a 5-HT1B/1D receptor agonist, and combined serotonergic stimulation may precipitate serotonin toxicity.
Clinical Significance
The FDA has issued warnings about this class combination; however, the absolute risk appears lower than with serotonin reuptake-inhibiting opioids.
Management
Use with caution; if the combination is required for migraine management in SSRI-treated patients, monitor for serotonin syndrome symptoms.